NICE rejects Janssen’s Stelara for moderate to severe ulcerative colitis
The National Institute for Health and Care Excellence (NICE) has not recommended ustekinumab, Janssen's Stelara, for treating moderately to severely active ulcerative colitis in...
Fewer than half of US clinical trials comply with law on reporting results
Research into reporting of US clinical trial results finds that less than half (41%) are reported promptly onto the US trial registry, and one...
Study confirms benefits of blood anticoagulants for heart failure patients
British clinical AI technology company Sensyne Health has announced its part in the results of a study seeking to identify if there are benefits...
Lynparza regulatory submission granted Priority Review in US
AstraZeneca and MSD have announced that a supplemental New Drug Application for Lynparza (olaparib) has been accepted and granted Priority Review in the US...
NICE wants more data on histology independent cancer treatments
The National Institute for Health and Care Excellence (NICE) is encouraging further data collection on ‘game changing’ histology independent cancer treatments. This comes as...
NICE approves Pfizer’s Ibrance in new combination for certain breast cancers
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following Pfizer's...
SMC recommends Roche’s Ocrevus®▼ for people with PPMS
The Scottish Medicines Consortium has approved Roche’s Ocrevus®▼ (ocrelizumab) through the Patient and Clinician Engagement (PACE) process for early primary progressive multiple sclerosis (PPMS)....
Acquisition of Ashfield Pharmacovigilance from UDG Healthcare
Ergomed plc has announced the acquisition of Ashfield Pharmacovigilance Inc from UDG Healthcare US Holdings, Inc., the US operating subsidiary of UDG Healthcare plc....
Bayer and Exscientia collaborate on AI in cardiovascular and oncology drug discovery
Bayer and Exscientia are to collaborate to leverage the potential of AI in cardiovascular and oncology drug discovery. Exscientia, the leading Artificial Intelligence (AI)-driven drug...
Hearing Medicines Discovery Syndicate launches
Action on Hearing Loss and Medicines Discovery Catapult have launched the Hearing Medicines Discovery Syndicate, a unique collaboration to accelerate the much-needed development of...
Latest articles
What’s been authorised? UK, Europe, US drug approvals
Pf summarises the UK, Europe and US drug approvals from 20 - 24 Jan 2020. UK The National Institute for Health and Care Excellence published draft...
Digital interventions for behaviour change
New NICE guidance looks at digital interventions for behaviour change and suggests that these interventions such as apps, wearable devices and online programmes and...
Acute aortic dissection is a ‘ticking time bomb’
Safety body calls for earlier recognition of ‘ticking time bomb’ aortic dissection to prevent deaths as its new report reveals that up to half...
Popular articles
NICE rejects Janssen’s Stelara for moderate to severe ulcerative colitis
The National Institute for Health and Care Excellence (NICE) has not recommended ustekinumab, Janssen's Stelara, for treating moderately to severely active ulcerative colitis in...
Meningitis B infant vaccination programme shows 75% drop in cases over three years
Meningitis B infant vaccination programme shows 75% drop in cases over three years, these are the results of one of two independent meningitis B...
AstraZeneca’s Tagrisso▼ (osimertinib) rejected by NICE for use in NHS England
The National Institute for Health and Care Excellence (NICE) has published final guidance that does not recommend AstraZeneca's Tagrisso▼ (osimertinib) for use within NHS...
Integrated commercial deployment in life sciences and other 2020 health trends
Syneos Health explore integrated commercial deployment in life sciences and discuss their new report covering 2020 health trends. Life science leaders aren’t launching with...
What’s been authorised? UK, Europe, US drug approvals
Pf summarises the UK, Europe and US drug approvals from 20 - 24 Jan 2020. UK The National Institute for Health and Care Excellence published draft...